Lupin has signed a non-exclusive patent license agreement with Takeda Pharmaceutical Company to commercialize Vonoprazan Tablets in the Indian market.

The drug will be marketed under the brand name Lupin’s Lupivon and will be available in two strengths: 10 mg and 20 mg.

Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India.

“We are very pleased to commercialize Vonoprazan, a novel treatment option for Acid Peptic Disorders. This is a further step in strengthening our gastroenterology portfolio and is in line with our commitment to introduce innovative medicines to address the unmet needs of our patients,” said Rajeev Sibal, President of India Region Formulations, Lupin. 

Acid Peptic Disorder (APD) which includes Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD), is a highly prevalent disorder in India. While the prevalence of GERD ranges from 5 percent to 28.5 percent, PUD has a prevalence in the range of ~ 8 percent. Risk factors for GERD include old age, high body mass index (BMI), non-vegetarian diet, tea/coffee intake, smoking and alcohol consumption.

Vonoprazan is a novel potassium-competitive acid blocker (P-CAB). Unlike traditional acid suppressants like PPIs, Vonoprazan offers unique attributes like complete proton pump inhibition with the first dose, longer duration of action resulting in effective control of nocturnal acid breakthrough, and meal-independent dosing.

In India, Vonoprazan is approved by the DCGI for treating reflux esophagitis, gastric ulcers, duodenal ulcers, and as part of Helicobacter pylori eradication treatment.